CAR-T therapy offers a new treatment modality for treating blood cancers which is complementary to the Group’s CDX bi-specific antibody program. The HEMO-CAR platform has shown in vivo anticancer activity and may be an attractive cancer treatment without the toxic side-effects of chemotherapy.
23 Jul 2020
The pipeline continues to grow
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The pipeline continues to grow
HemoGenyx Pharmaceuticals Plc (HEMO:LON) | 1.6 0 (-3.1%) | Mkt Cap: 22.1m
- Published:
23 Jul 2020 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
15
CAR-T therapy offers a new treatment modality for treating blood cancers which is complementary to the Group’s CDX bi-specific antibody program. The HEMO-CAR platform has shown in vivo anticancer activity and may be an attractive cancer treatment without the toxic side-effects of chemotherapy.